Are you using biomarker testing to confirm treatment decisions in NSCLC?

Visit HopeinRET.com

Hope is in bloom in RET+ NSCLC

[pick list]
[Dear]
[Hello]

[pick list]
[First Name],
[First Name Last Name],
[Dr. Last Name],

[pick list]
false[I appreciate that your time is valuable. When you're available, I'd like to speak with you about the importance of biomarkers, like RET, and comprehensive biomarker testing in NSCLC.] true[Thank you for taking time out of your busy day to speak with me.] true[I wanted to check in with you and see how things are going.]

There are more targeted therapies available today than ever before for the treatment of metastatic non–small cell lung cancer (NSCLC). In fact, there are now 7 actionable biomarkers with approved targeted therapies. Up to 69% of patients with NSCLC could have a potentially actionable biomarker.^1,2

It's important to identify biomarkers with broad molecular testing like next generation sequencing and, if clinically appropriate, wait for test results to confirm treatment.^3,4

To identify oncogenic drivers, such as RET, in eligible patients with metastatic NSCLC, and to determine if these patients are eligible for targeted therapy, the National Comprehensive Cancer Network^® (NCCN^®) NSCLC Panel recommends molecular testing for actionable biomarkers, including RET, and strongly advises broad molecular profiling.⁵*

I’ve included some information I hope you’ll find useful.

[email fragments]

RET+ NSCLC Disease Education Flashcard

Information on RET+ NSCLC and the importance of comprehensive biomarker testing in NSCLC.

Expert Insights Video: Dr. Burns' Overview of Biomarker Testing in NSCLC

See what Dr. Timothy Burns, medical oncologist at UPMC Hillman Cancer Center, has to say about the importance of biomarker testing.

Visit the HopeinRET.com Website

Read more about RET+ NSCLC and biomarker testing at the official "Hope Is in Bloom in RET+ NSCLC" website.

I would be happy to set up a quick [pick list] [ falsecall truevideo chat truemeeting ] to discuss any questions you have. Please feel free to contact me at [pick list] [ falserep email truerep phone number ].

[pick list]
false [Sincerely,] true [Best,]

[Rep photo]

[Rep name]
[Rep title]

*	The NCCN Guidelines^® for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

NCCN=National Comprehensive Cancer Network^®; NSCLC=non–small cell lung cancer; RET=rearranged during transfection.

References: 1. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299-311.
2. LUNGevity Foundation. Targeted therapy. https//lungevity.org/for-patients-caregivers/lung-cancer-101/treatment-options/targeted-therapy. Accessed June 4, 2020. 3. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Canc Res. 2017;23(8):1988-1997. 4. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^©) for Non-Small Cell Lung Cancer V.6.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July 20, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.

This e-mail is intended for U.S. healthcare professionals only.

Blueprint Medicines and associated logo are trademarks of

Blueprint Medicines Corporation.

Blueprint Medicines Corporation
45 Sidney Street, Cambridge, MA 02139

08/2020 USBP-DAP-20-021.1